drugset / Trial / NCT05391893

Effect of Oral and Intravenous Diltiazem Protocol for Emergency Department Atrial Fibrillation

NCT05391893

Phase 4 Completed 444 enrolled Corewell Health South
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of the study is to reduce hospital admission and decrease time to disposition through establishing an effective treatment protocol for AF and Atrial Flutter in the Emergency Department of Spectrum Health Lakeland. Secondary outcome is to measure if oral diltiazem is an effective HR controlling agent in AF RVR and Flutter.

Timeline

Start
2020-06-19
Primary completion
2023-04-01
Completion
2023-04-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator Diltiazem Small molecule 60 mg Oral
Comparator Amiodarone Small molecule
Comparator Digoxin Other / unclassified